Patient disposition at last contact
| . | ≥ 65 y (115 pts), n (%) . | < 65 y (444 pts), n (%) . | P . |
|---|---|---|---|
| Still on imatinib | 75 (65) | 327 (74) | .08 |
| Off imatinib | 40 (35) | 117 (26) | |
| Second-generation TKIs | 8 (7) | 51 (11) | .008 |
| Other (SCT; HU; IFNα) | 3 (3) | 18 (4) | .28 |
| Deaths | 23 (20) | 31 (7) | .0009 |
| Unknown | 6 (5) | 17 (4) | > .999 |
| . | ≥ 65 y (115 pts), n (%) . | < 65 y (444 pts), n (%) . | P . |
|---|---|---|---|
| Still on imatinib | 75 (65) | 327 (74) | .08 |
| Off imatinib | 40 (35) | 117 (26) | |
| Second-generation TKIs | 8 (7) | 51 (11) | .008 |
| Other (SCT; HU; IFNα) | 3 (3) | 18 (4) | .28 |
| Deaths | 23 (20) | 31 (7) | .0009 |
| Unknown | 6 (5) | 17 (4) | > .999 |
At last contact, the proportion of patients still on imatinib, although higher for younger ones, was not statistically different among the 2 groups of patients. A higher proportion of younger patients received a second generation TKIs, while deaths were more frequent in the older cohort.
TKIs indicates tyrosine kinase inhibitors; SCT, stem cell transplantation; HU, hydroxyurea; and IFNα, interferon alpha